Telix Pharmaceuticals (TLX) Morgan Stanley 24th Annual Global Healthcare Conference summary

Regulatory milestones and product innovation

• Achieved FDA approval for PIXCLARA, the first imaging agent for glioma, with plans for label expansion through ongoing clinical trials targeting broader indications and metastatic disease.

• Emphasized the complementary nature of imaging and therapeutics, with TLX101 in phase III and a strategy informed by previous drug approvals.

• Highlighted the importance of patient selection and treatment response assessment using imaging, especially in complex diseases like glioma.

• Ongoing efforts to align product labels with broader clinical practice guidelines and expand market opportunities through additional indications.

• Resubmission for Zircaix approval is imminent, with expectations for regulatory progress in 2024.

Market strategy and operational integration

• Adopted a dual approach to manufacturing and distribution, integrating both centralized production and nuclear pharmacy networks for last-mile delivery.

• Strategic acquisitions, such as RLS, have strengthened distribution capabilities and provided a competitive edge in controlling product delivery.

• Vertical integration across the value chain, including supply chain, manufacturing, and sales force, is a key focus to ensure operational excellence.

• Specialized commercial teams, including field market access and clinical specialists, support customer adoption and market leadership.

• Pricing strategies for niche products like PIXCLARA reflect their specialist nature and customization needs.

Pipeline development and clinical progress

• Precision Medicine growth is driven by the PSMA franchise, with continued expansion into neuro-oncology and kidney cancer diagnostics.

• BiPASS trial aims to transform prostate cancer diagnosis by reducing unnecessary biopsies, leveraging PSMA PET scans for better patient outcomes.

• TLX591 and TLX597 are positioned for different stages of prostate cancer, with phase III trials ongoing and innovative dosing strategies to improve patient experience and outcomes.

• Clinical data from studies like PRIMARY and BiPASS underpin confidence in new diagnostic pathways and support regulatory submissions.

• Partnerships, such as with Regeneron, focus on developing next-generation radiopharmaceuticals by combining expertise in biologics and radiopharma.